It is increasingly recognised that chronically activated glia contribute to the pathology of various neurodegenerative diseases, including glaucoma. One means by which this can occur is through the release of neurotoxic, proinflammatory factors. In the current study, we therefore investigated the spatio-temporal patterns of expression of three such cytokines, IL-1β, TNFα and IL-6, in a validated rat model of experimental glaucoma. First, only weak evidence was found for increased expression of IL-1β and TNFα following induction of ocular hypertension. Second, and much more striking, was that robust evidence was uncovered showing IL-6 to be synthesised by injured retinal ganglion cells following elevation of intraocular pressure and transported in an orthograde fashion along the nerve, accumulating at sites of axonal disruption in the optic nerve head. Verification that IL-6 represents a novel marker of disrupted axonal transport in this model was obtained by performing double labelling immunofluorescence with recognised markers of fast axonal transport. The stimulus for IL-6 synthesis and axonal transport during experimental glaucoma arose from axonal injury rather than ocular hypertension, as the response was identical after optic nerve crush and bilateral occlusion of the carotid arteries, each of which is independent of elevated intraocular pressure. Moreover, the response of IL-6 was not a generalised feature of the gp130 family of cytokines, as it was not mimicked by another family member, ciliary neurotrophic factor. Finally, further study suggested that IL-6 may be an early part of the endogenous regenerative response as the cytokine colocalised with growth-associated membrane phosphoprotein-43 in some putative regenerating axons, and potently stimulated neuritogenesis in retinal ganglion cells in culture, an effect that was additive to that of ciliary neurotrophic factor. These data comprise clear evidence that IL-6 is actively involved in the attempt of injured retinal ganglion cells to regenerate their axons.
Introduction
Glaucoma is a progressive, intraocular pressure (IOP)-sensitive optic neuropathy with a poorly understood pathogenesis and limited treatment options (Chidlow et al., 2007) . The disease, which is the most common cause of irreversible blindness worldwide (Quigley and Broman, 2006) , is characterised by structural damage to the optic nerve (ON) and the progressive death of retinal ganglion cells (RGCs). Converging clinical (Quigley, 2011) and experimental (Howell et al., 2007; Vidal-Sanz et al., 2011) data have led to a prevailing belief that the primary site of injury in glaucoma occurs at the optic nerve head (ONH). A recent study by ourselves corroborates this viewpoint: using a validated, experimentally-induced rat model of glaucoma, we demonstrated that the ONH is the pivotal site of axonal transport disruption and axonal cytoskeletal damage following moderate elevation of IOP, with subsequent anterograde degeneration of axons and retrograde death of RGC somas (Chidlow et al., 2011b) .
A number of theories have been proposed to account for the susceptibility of the ONH to glaucomatous injury. Of these, the most commonly advocated are the "mechanical" and "vascular" theories (Fechtner and Weinreb, 1994) . The former hypothesis contends that elevated IOP causes physical constriction to axon bundles, thereby disrupting axoplasmic transport (Burgoyne et al., 2005; Quigley, 1999) . Damage to axons may also occur indirectly via the release of toxic substances from mechanically distorted local glia. The latter hypothesis proposes that axonal and glial components of the ONH undergo chronic hypoxic or ischemic injury as a result of compromised local blood flow, resulting from either increased IOP or other risk factors that lead to vascular dysregulation (Flammer et al., 2002; Yanagi et al., 2011) . The ONH is considered especially susceptible to a decreased nutrient supply owing to its high density of mitochondria, which are required to serve the considerable energy requirements of the unmyelinated axons of the prelaminar and laminar ON (Barron et al., 2004) .
A common element to both theories relates to the potential involvement of resident ONH glial cells. Activated glia are increasingly suspected to play a leading role in the pathogenesis of glaucoma (Bosco et al., 2011; Hernandez et al., 2008; Johnson and Morrison, 2009; Yuan and Neufeld, 2001) , but knowledge of the actual processes involved remains largely speculative. Glial cells are known to modify their gene expression profiles in response to homeostatic imbalance, potentially triggering or exacerbating neuronal damage if persistently activated. One such mechanism by which this can occur is via the synthesis and release of proinflammatory cytokines, notably tumor necrosis factor-α (TNFα), interleukin (IL)-1β and IL-6 (Hanisch, 2002) . There exists persuasive evidence for the causal involvement of glia-derived TNFα and IL-1β in the pathogenesis of white matter injuries in the CNS induced by hypoxic and mechanical insults, such as chronic cerebral hypoperfusion (Tomimoto et al., 2003) , neonatal hypoxia-ischemia (Deng et al., 2011) and spinal cord compression (Esposito and Cuzzocrea, 2011) . The situation regarding IL-6, however, is less straightforward, with this cytokine exerting beneficial as well as detrimental effects depending on the pathological context (Suzuki et al., 2009 ). In the eye, an accumulating body of data points to a detrimental role for TNFα: the cytokine is toxic to both RGC somas (Berger et al., 2008) and axons (Kitaoka et al., 2006; Nakazawa et al., 2006) , and has been shown to be upregulated by ONH glia in glaucomatous patients (Yuan and Neufeld, 2000) . Little is known about the involvement of IL-1β and IL-6 in glaucoma, with cell culture studies suggesting a neuroprotective role for IL-6 (Sappington et al., 2006) .
The primary goal of the current study was to further our knowledge of the pathology of experimental glaucoma by focussing on the spatio-temporal patterns of expression of the proinflammatory cytokines IL-1β, TNFα and IL-6. We hypothesised that the early disruption to axonal homeostasis that occurs in our experimental glaucoma model would correlate with an upregulation of proinflammatory cytokines by resident glia, and, that the extent of expression would rise during the subsequent axonal degeneration phase, concurrent with increasing glial activity.
Materials and methods

Animals and procedures
This study was approved by the Animal Ethics Committees of the Institute of Medical and Veterinary Science and the University of Adelaide and conforms with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, 2004 . All experiments also conformed to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Adult Sprague-Dawley rats (200-250 g) were housed in a temperature-and humidity-controlled environment with a 12-h light, 12-h dark cycle and were provided with food and water ad libitum.
For establishment of experimental glaucoma, rats were anaesthetised with 100 mg/kg ketamine and 10 mg/kg xylazine. Ocular hypertension was then induced in the right eye of each animal by laser photocoagulation of the trabecular meshwork using a slightly modified protocol (Ebneter et al., 2010) of the method described by Levkovitch-Verbin et al. (2002) . For 14 day rats, a second laser treatment was given on day 7 if the difference in IOP between the two eyes was less than 8 mm Hg. IOPs were measured in both eyes at baseline, 8 h, day 1, day 3, day 7 and day 14 using a rebound tonometer factory calibrated for use in rats. All animals demonstrated an adequate IOP elevation (minimum increase in IOP of 10 mm Hg) and therefore none were excluded from the study. 3 animals were excluded as a result of death under anaesthesia and 3 due to hyphema. Two cohorts of rats were used in the current study. The first cohort was used for immunohistochemistry/ histology: the number of rats analysed at each time point was as follows: 8 h (n=5), 1 day (n=8), 3 days (n=9), 7 days (n=13), 14 days (n=21). IOP data for these rats are provided (see Table 2 ). In addition, 3 rats were killed at 2 days and transverse sections taken through the ONH, and, 5 rats were killed at 1 day and used for ELISA analysis. For axonal tracing, 4 rats were injected intravitreally with 5 μl of 0.1% AlexaFluor 594-conjugated cholera toxin β-subunit (CTB) dissolved in sterile PBS. After 24 h, the right eyes were laser-treated as above. Rats were killed after 2 days and tissues removed for immunohistochemistry. The second cohort was used for RT-PCR. The number of rats analysed at each time point was as follows: 1 day (n=7), 3 days (n=13), 7 days (n=13), 14 days (n=7). The chiasm from each rat was taken for immunohistochemistry to verify that the procedure had induced an injury response commensurate with the first cohort.
For endotoxin-induced retinal inflammation, an intravitreal injection of 0.2% lipopolysaccharide (LPS; 5 μl in sterile saline) was performed in one eye. For excitotoxicity experiments, an intravitreal injection of 40 nmol of NMDA (5 μl in sterile saline) was performed in one eye. In each case, the contralateral eye received 5 μl of sterile saline. All rats (NMDA, n=4; LPS, n=4 for immunohistochemistry, n=4 for ELISA) were killed after 6 h. ON crush was performed as previously described (Chidlow et al., 2011b) . In brief, the superior muscle complex was divided and the ON exposed by blunt dissection. The ON was then crushed 3 mm posterior to the globe under direct visualisation using number 5 forceps for 20 s. To avoid confusing retinal ischemic changes with the effects of crush, the fundus was observed ophthalmologically immediately after nerve crush, in order to discard any animals with perfusion dysfunction as a result of surgery. A total of 12 rats were subjected to ON crush and these were killed after either 1 day (n=6) or 14 days (n=6). Bilateral occlusion of the common carotid arteries (2VO) was performed as previously described . In brief, rats were anaesthetised and a ventral incision was made. The common carotid arteries were then bilaterally separated from the carotid sheath and vagus nerve. The arteries were ligated with silk sutures. Sham animals received the same operation without occlusion of the vessels. A total of 4 rats were subjected to 2VO, which were killed after 2 days.
Tissue processing and histology
All rats were killed by transcardial perfusion with physiological saline under deep anaesthesia. In those rats where tissue was not taken for RT-PCR, perfusion with 4% (w/v) paraformaldehyde was also subsequently undertaken. Each eye with ON, optic chiasm and the proximal part of the optic tract attached was carefully dissected. From the dissected tissue, a short piece of ON (2 mm long), 1.5 mm behind the globe, was removed for resin embedding. The globe, remaining ON, chiasm and proximal segment of optic tract were fixed in 10% buffered formalin for at least 24 h and then processed for routine paraffin-embedding. Globes were embedded and sectioned sagitally; ONs and chiasmata, longitudinally. In all cases, 4 μm serial sections were cut. As detailed above, 3 rats killed at 2 days were used for transverse sectioning of the ONH. The short piece of proximal ON taken for resin sectioning and toluidine blue staining was treated as previously reported (Ebneter et al., 2010) .
Immunohistochemistry
Fluorescent immunohistochemistry was performed as previously described (Chidlow et al., 2011a,b) . Following deparaffinisation, antigen retrieval was achieved by microwaving the sections in 10 mM citrate buffer (pH 6.0). Sections were then blocked in PBS containing 3% normal horse serum and incubated overnight in primary antibody, followed by consecutive incubations with biotinylated secondary antibody and streptavidin-conjugated AlexaFluor 594. Sections were mounted using anti-fade mounting medium. Specificity of antibody labelling was confirmed by incubating adjacent sections with mouse IgG1 isotype controls for monoclonal antibodies, or normal rabbit/ goat serum for polyclonal antibodies. Primary antibody details are provided in Supplementary Table 1. To confirm the validity of negative findings, the following alternate antibodies were also tested: rabbit anti-IL-1β (ab9787, Abcam); rabbit anti-TNFα (HP8001, Hycult).
For double labelling fluorescent immunohistochemistry, visualisation of one antigen was achieved using a 3-step procedure (primary antibody, biotinylated secondary antibody, streptavidin-conjugated AlexaFluor 594), whilst the second antigen was labelled by a 2-step procedure (primary antibody, secondary antibody conjugated to AlexaFluor 488). Sections were prepared as above, then incubated overnight at room temperature in the appropriate combination of primary antibodies. On the following day, sections were incubated with the appropriate biotinylated secondary antibody (1:250) for the 3-step procedure plus the correct secondary antibody conjugated to AlexaFluor 488 (1:250, Invitrogen) for the 2-step procedure for 30 min, followed by streptavidin-conjugated AlexaFluor 594 (1:500) for 1 h. Sections were then mounted using anti-fade mounting medium and examined under a confocal fluorescence microscope.
ONH accumulation of β-amyloid precursor protein (APP), IL-6 and growth-associated membrane phosphoprotein-43 (Gap43) was assessed semi-quantitatively using a 5-point grading system, ranging from 0 = undetectable to 4 = numerous intensely-stained immunopositive axons covering a substantial area of the prelaminar to post-laminar ONH. Statistical analysis of APP grade vs IL-6 grade was by Wilcoxon signed-rank test with modified Bonferroni correction.
Terminal deoxynucleotidyl transferase (TdT)-mediated, dUTP nick end labelling (TUNEL) was performed as described previously (Chidlow et al., 2009 ).
ELISA
The level of IL-6 in retinal samples was estimated using an enzyme-linked immunosorbent assay (Quantikine®, R&D Systems). Retinas from control, LPS-treated, and experimental glaucoma rats were carefully dissected, immediately sonicated in PBS containing protease inhibitors, then snap frozen and stored at −70°C. On the day of the assay, samples were thawed, centrifuged at 13,000 ×g, and the supernatant extracted for use in ELISA and for protein measurement. The ELISA assay was conducted according to instructions, whilst the amount of protein was determined using a routine methodology.
Electrophoresis/Western blotting
Electrophoresis/Western blotting was performed as previously described . In brief, recombinant proteins for rat TNFα (510-RT-050), rat IL-1β (510-RL-050) and rat IL-6 (506-RL-050) were obtained (RnD Systems) and diluted to provide samples containing 1, 10 and 10 ng of each protein. After electrophoresis, samples were transferred onto PVDF membranes. Following a block of non-specific binding, blots were probed by sequential incubations with primary antibodies (Supplementary Table 1 ), appropriate secondary antibodies conjugated to biotin, and streptavidinperoxidase conjugate. Blots were then developed and the images captured.
Real-time RT-PCR
Reverse-transcription polymerisation chain reaction (RT-PCR) studies were carried out as described previously (Chidlow et al., 2008) . In brief, retinas were dissected, total RNA was isolated and first strand cDNA was synthesised from 2 μg DNase-treated RNA. Real-time PCR reactions were carried out in 96-well optical reaction plates using the cDNA equivalent of 20 ng total RNA for each sample in a total volume of 25 μl containing 1× SYBR Green PCR master mix (BioRad), forward and reverse primers at a final concentration of 400 nM. The thermal cycling conditions were 95°C for 3 min and 40 cycles of amplification comprising 95°C for 12 s, 63°C for 30 s and 72°C for 30 s. Primer sets used were as follows (sense primer, antisense primer, product size, accession number): GAPDH (5′-TGCACCACCAACTGCTTAGC-3′, 5′-GGCATGGACTGTGGTCATGAG-3′, 87 bp, GenBank ID: NM_017008), TNFα (5′-AAATGGGCTCCCTCTCATCAGTTC-3′, 5′-TCTGCTTGGTGGTTTG CTACGAC-3′, 111 bp, GenBank ID: NM_012675), IL-1β (5′-CACCTCTCAA GCAGAGCACAG-3′, 5′-GGGTTCCATGGTGAAGTCAAC-3′, 79 bp, GenBank ID: NM_031512), IL-6 (5′-TGCCTATTGAAAATCTGCTCTGG-3′, 5′-ATTGGA AGTTGGGGTAGGAAGG-3′, 189 bp, GenBank ID: NM_012589). Results obtained from the real-time PCR experiments were quantified using the comparative threshold cycle (C T ) method (ΔΔC T ) for relative quantitation of gene expression (Livak and Schmittgen, 2001) , corrected for amplification efficiency (Pfaffl, 2001) . All values were normalised using the endogenous housekeeping gene GAPDH and expressed relative to controls. Statistical analysis was carried out by ANOVA followed by post-hoc Scheffe test. The null hypothesis tested was that C T differences between target and housekeeping genes would be the same in control and experimental retinas.
Adult rat RGC cultures
Adult Sprague-Dawley rats were euthanised by CO 2 asphyxiation and their eyes enucleated. The retina from each eye was dissected, cut into small pieces, incubated in activated papain solution (2 mg/ml papain, 0.4 mg/ml DL-cysteine, 0.4 mg/ml bovine serum albumin, in Neurobasal medium) for 25 min at 37°C and then washed three times with RGC culture medium (Neurobasal medium with B27 nutrient supplement, 100 U/ml penicillin, 100 U/ml streptomycin, 1 mM sodium pyruvate, 2 mM L-glutamine, 5 μg/ml insulin, 100 μg/ml transferrin, 100 μg/ml bovine serum albumin, 60 ng/ml progesterone, 16 μg/ml putrescine, 40 ng/ml sodium selenite, 40 ng/ml L-thyroxine, 40 ng/ml tri-iodothyronine, 5 μM forskolin and 1% [v/v] foetal bovine serum). Retinal pieces were triturated by gently passing through fire-polished disposable glass Pasteur pipettes until full cell dispersion had taken place. Cell suspensions were dispensed onto 13 mm borosilicate glass coverslips previously coated sequentially with poly-D-lysine (5 μg/ml, overnight) and laminin (1 μg/ml, 90 min) at the density of approximately 1 × 10 6 cells per well. In general, cells were cultured in RGC culture medium plus growth factor mix (50 ng/ml BDNF, 10 ng/ml CNTF, 10 ng/ml bFGF) at 37°C, with saturating humidity and 5% (v/v) CO 2 , for up to 30 days, and with medium being changed every 3 days after the first 7 days in vitro. Cells were treated with growth factors, including with recombinant rat IL-6 (1.33 μg/ml) from day zero (harvesting day) onwards. The study design included four groups delineated as follows: (1) no growth factor mix and no IL-6, (2) growth factor mix with no IL-6, (3) no growth factor mix but plus IL-6, (4) plus growth factor mix and IL-6. This treatment regime enabled determination of whether IL-6 could instigate neuritogenesis or could only assist propagation of existing neurite buds (as stimulated by growth factor mix). Cells on coverslips were fixed 7 days after culture/treatment with 10% buffered formalin and then were immunocytochemically double labelled with rabbit anti-tau, which labelled cell bodies and all neurites, and mouse anti-GAP43, which labelled all new growing neurites. Coverslips were mounted face-side down and microscopically analysed with immunofluorescence optics. To quantify the effect of IL-6 on neuritogenesis, triplicate coverslips were treated with the additives described above, from four individual cultures. From each coverslip, eight individual RGCs were selected and analysed using the Simple Neurite Tracer add-on for ImageJ (Pool et al., 2008) . For each RGC analysed, parameters which were determined were the number of neurites branching out from the perikaryon and the mean length of the major neurite (rounded to the nearest 25 μm). Statistical analysis was by Kruskal-Wallis one-way analysis of variance, followed by Dunn's Multiple Comparison Test.
Results
Validation of the IL-1β, TNFα and IL-6 antibodies
Acquisition of biologically meaningful immunohistochemical data from paraffin-embedded tissue requires the use of validated antibodies within the context of an optimised methodology. Publication of false-negative and -positive findings in the field of Neuroscience is of legitimate concern (Saper 2005; Rhodes and Trimmer 2006; Fritschy 2008) . Initially, therefore, we sought to verify that the selected antibodies recognised their appropriate targets, and, that each yielded high signal-to-background labelling. To achieve this aim, we performed Western blotting of recombinant rat IL-1β, TNFα and IL-6 proteins with the antibodies in question. Next, we analysed retinal sections from control eyes and from eyes injected with the proinflammatory endotoxin LPS, which is known to induce microglia to synthesise IL-1β, TNFα and IL-6 (Mertsch et al., 2001 ). The LPS tissue acted as a positive control, since expression of IL-1β, TNFα and IL-6 is minimal in control retinas. Supplementary Fig. 1 shows results obtained with the selected IL-1β and TNFα antibodies. Both antibodies detected concentration-dependent, single proteins at the expected molecular weights. LPS induced upregulation of both molecules within discrete populations of cells in the inner retina. Double labelling with the microglial-specific marker iba1 indicated that expression of each of the cytokines was, as expected, restricted to this cell type.
Four different IL-6 antibodies (see Supplementary Fig. 2 ) were analysed for their utility. Western blotting of recombinant rat IL-6 indicated that three of the four antibodies produced clean, concentration-dependent bands at the correct molecular weight ( Supplementary Fig. 2 ). Next we assessed immunolabelling in paraffin-embedded retinal sections. None of the four antibodies showed any immunoreactivity in sections from control animals (data not shown). One of the antibodies (R&D Systems, cat# AF506) discretely labelled a population of cells in the LPS-treated retina with a high signal-to-noise ratio. Successful colocalisation with iba1 and IL-1β demonstrated that these cells are activated microglia. Immunolabelling was abolished in the absence of secondary antibody and was abolished by preadsorption with the recombinant IL-6 protein ( Supplementary Fig. 3 ). The other three antibodies failed to provide positive immunolabelling in LPS-treated retinas (Supplementary Fig. 4 ). As such, they were not used in the remainder of the study.
Expression of IL-1β, TNFα and IL-6 by microglia after NMDA-induced excitotoxicity
Prior to investigating the association of IL-1β, TNFα and IL-6 with experimental glaucoma, we examined expression of the cytokines following N-methy-D-aspartate (NMDA) treatment. NMDA-induced excitotoxicity is the classical method of inducing somato-dendritic death of RGCs. As such, the results assist contextualizing those obtained from the experimental glaucoma model, which causes initial damage to RGC axons at the site of the ONH rather than to the perikarya (Chidlow et al., 2011b) . The results obtained were very similar to those yielded after LPS treatment, namely rapid (i.e. by 6 h) inductions of all three cytokines, with expression limited to microglia located in the inner retina (Fig. 1) . At 1 day after NMDA treatment microglia were no longer observed to express IL-1β, TNFα and IL-6 (data not shown).
Temporal analysis of IL-1β, TNFα and IL-6 mRNA expression during experimental glaucoma
To elucidate the timing and extent of any changes in expression of IL-1β, TNFα and IL-6 in the retina following elevation of raised IOP, we quantified the mRNAs encoding these proteins using real-time RT-PCR (Fig. 2) . Expression of IL-1β mRNA was unaltered at 24 h after induction of ocular hypertension, the earliest time point analysed. Thereafter, the IL-1β mRNA level in the retina was found to be consistently greater in the treated animals than in the control group (3.5-fold higher at 3 days, 3.8-fold higher at 7 days, 4.3-fold higher at 14 days). Each of these differences was statistically significant. The level of TNFα in treated retinas was statistically higher than in controls at all four time points analysed with the largest differential between treated and control animals (3.9-fold) occurring 24 h after laser-treatment. IL-6 mRNA was more robustly upregulated than either IL-1β or TNFα mRNAs in response to elevated IOP. At 24 h, IL-6 mRNA in treated retinas was 7.4-fold higher than in the control group. Thereafter, the level of IL-6 mRNA gradually diminished over time.
Expression of IL-1β and TNFα during experimental glaucoma Retina
Despite the evidence of moderate IL-1β and TNFα mRNA upregulations in response to elevated IOP, analysis of the corresponding immunoreactivities failed to reveal any positive cellular labelling in any of the animals at any of the time points analysed, which ranged from 8 h to 14 days (Figs. 3A,B) . For example, at 24 h after induction of ocular hypertension, no TNFα immunoreactivity was observed in iba1-positive microglia, or in astrocytes or Müller cells, both of which featured enhanced expression of the intermediate filament GFAP, or in neurons. Similarly, at 14 days, a time point when significant RGC death has occurred (Chidlow et al., 2011b) and activated iba1-positive microglia are numerous, no IL-1β immunoreactivity was detectable in any retinal cell type.
Optic nerve head
We have recently shown that the earliest indication of damage following chronic elevation of IOP is axonal transport failure within RGC axons as they pass through the ONH (Chidlow et al., 2011b) . Since microglia are rapidly activated by even minor homeostatic imbalance, it is of interest to determine whether this event, or the axonal cytoskeletal damage that occurs subsequently, triggers increased expression of the proinflammatory cytokines IL-1β and TNFα. The results indicate not. At 24 h (Fig. 3C ), widespread accumulation of APP was evident in injured axons in the ONH of treated eyes, but no expression of IL-1β or TNFα was detectable. Similarly, after 3 days of raised IOP (Fig. 3D) , when the number of microglia in the ONH had increased and the majority of these cells displayed an activated morphology (Ebneter et al., 2010) , there was no discernible expression of IL-1β or TNFα. Analysis of animals killed at later time points produced the same results. In order to verify that these negative findings were genuinely representative, we probed sections with alternate IL-1β and TNFα antibodies (see Materials and methods) that we had previously validated in LPS-injected eyes. As expected, the results were identical (data not shown).
Expression of IL-6 during experimental glaucoma
Immunolabelling for IL-6 in rats subjected to experimental glaucoma produced results as striking as they were unexpected. Following induction of elevated IOP, expression of IL-6 was associated not with glia, but with injured RGC axons (see Figs. 4-6) . As early as 8 h after laser treatment, IL-6 began to accumulate at the ONH (Fig. 4A) . By 24 h, intense IL-6 immunoreactivity was observed throughout the ONH, a result that was typical of the majority of rats analysed within the first few days (Figs. 4A, 5A-C) . Labelling of transverse sections of the ONH and proximal ON in rats that had undergone 2 days of elevated IOP revealed an asymmetric, regionalised pattern of IL-6 expression within the unmyelinated laminar segment of the nerve (Fig. 4B ), but no presence distal to this site in the myelinated portion of the ON (Fig. 4B ) and optic tract (data not shown). The abundance of IL-6 immunoreactivity in the ONH progressively diminished at 7 days and 14 days (Fig. 4A) , paralleling the decline in IOP. In the retina, IL-6 immunoreactivity was barely detectable in control eyes, but was upregulated in RGC somas that had been subjected to a week of elevated IOP and was visible in some axons in the nerve fibre layer (Fig. 4C) .
In order to verify the results from the immunohistochemistry experiments, which documented a striking upregulation of IL-6 by 24 h after induction of raised IOP, and, to provide a more quantitative analysis of the level of IL-6 protein expression, we performed an ELISA. The results, displayed in Table 1, confirm that the retinal level of IL-6 is significantly elevated when compared with unlasered retinas.
The overall pattern of IL-6 immunoreactivity during experimental glaucoma displayed a remarkable similarity to that of the stereotypical marker of fast axonal transport, APP (Chidlow et al., 2011b) , arguing strongly that IL-6 is synthesised by RGCs following elevation of IOP and transported in an orthograde fashion along the nerve until accumulating at sites of axonal disruption in the ONH. To investigate whether IL-6 is indeed a novel marker of disrupted axonal transport in this model, we performed double labelling experiments with various axonal and glial markers in rats that had undergone chronic ocular hypertension. Values (represented as mean ± SEM) are normalised for GAPDH and expressed relative to the control group. **P b 0.01, ***P b 0.001 by one-way ANOVA followed by post-hoc Scheffe test, where n = 40 (control), n = 7 (1 day), n = 13 (3 days), n = 13 (7 days), n = 7 (14 days).
Colabelling of IL-6 with an axonal structural marker, neurofilament light, revealed an overlap of immunoreactivities, which was particularly evident in injured axons displaying neurofilament abnormalities (Figs. 5D-F) . Colabelling of IL-6 with recognised endogenous markers of fast axonal transport, including APP (Figs. 5G-I ) and synaptophysin (data not shown), and with the neural tracer cholera toxin β-subunit (CTB; Figs. 5J-L) also demonstrated that IL-6 colocalised with all three axonal markers. In contrast, there was no colocalisation between IL-6 and the microglial marker iba1 (Figs. 6A-C) , between IL-6 and the Müller cell marker glutamine synthetase (Figs. 6D-F) and between IL-6 and the astrocytic marker GFAP (Figs. 6G-I ), indicating that IL-6 immunoreactivity likely resided solely within axons.
To provide a direct, quantitative comparison between IL-6 and APP, representative sections from the central ONH of every rat were labelled for both markers and graded for abundance of immunoreactivity using a 5 point grading scheme (see Materials and methods). The results showed an excellent agreement between IL-6 and APP at the 24 h, 1 day, 3 days and 7 days time points (Table 2 ; P > 0.5 by Wilcoxon signed-rank test with modified Bonferroni correction for APP versus IL-6 at each of the time points; r = 0.85, P b 0.001 by Spearman's Rank correlation for the combined data). Interestingly, however, at the 14 days time point, IL-6 was significantly more abundant than APP (P b 0.05 by Wilcoxon signedrank test with modified Bonferroni correction), suggesting that at this later time point IL-6 may not simply represent a marker of axonal transport disruption.
Expression of CNTF during experimental glaucoma
IL-6 is a member of the family of cytokines, with overlapping, pleiotropic activities, that all induce signalling through the common transmembrane receptor subunit gp130 (Suzuki et al., 2009) . To elucidate whether the response of IL-6 during experimental glaucoma is a generalised feature of the gp130 family of cytokines, we investigated expression of an additional, widely-studied member of the family, ciliary neurotrophic factor (CNTF). In normal adult rat retinas, CNTF immunoreactivity was localised to astrocytes and, to a lesser extent, Müller cells (Fig. 7A) . Following induction of elevated IOP, upregulated expression of CNTF was observed in both glial cell types, but no immunoreactivity was associated with neurons (Figs. 7B,C) . In the ONH and proximal ON of normal rats, CNTF expression was likewise restricted to glial cells (Figs. 7D,G) . After induction of experimental glaucoma, modest upregulation of CNTF signal was observed in glial cell columns (Figs. 7E,H,I ), but CNTF failed to colocalise with markers of axonal transport (Fig. 7F) .
Expression of IL-6 in other models of RGC axonal injury
The results detailed above show that IL-6 is synthesised by RGCs during experimental glaucoma and that this factor accumulates at sites of axonal disruption in the ONH; however, it is unknown whether the signalling pathway that induces expression of IL-6 by RGC somas derives from elevated IOP per se or from retrograde signals emanating from the nerve at the site of injury. To address this issue, we investigated IL-6 expression after ON crush (Fig. 8A, Table 2 ) and bilateral occlusion of the common carotid arteries (2VO; Fig. 8B ). ON crush causes axonal damage via mechanical trauma at the lesion site in the proximal ON, whilst 2VO drastically affects the vascular supply to the proximal ON, producing an infarct . Importantly, both models cause damage to the proximal ON without elevating IOP.
At 1 day after ON crush, extensive accumulation of the axonallytransported proteins APP and synaptophysin could be observed proximal to the crush site; IL-6 accumulated in an analogous manner. APP and synaptophysin could also be seen accumulating on the distal side of the lesion, indicating that these proteins are also normally transported retrogradely along the ON. IL-6, in contrast, was not detectable on the distal side of the lesion, suggesting that the cytokine is not routinely transported bilaterally (Fig. 8A) . At 14 days after ON crush, little axonal APP immunoreactivity remained; however, as was the case in experimental glaucoma, IL-6-positive axons were still frequently observed at this later time point. Grading of ON sections verified that IL-6 was significantly more abundant than APP (P b 0.05 by Wilcoxon signed-rank test with modified Bonferroni correction; Table 2 ).
At 2 days after 2VO, TUNEL labelling highlighted the appearance of an infarct in the proximal ON, just distal to the ONH (Fig. 8B ). IL-6 and APP were both observed to accumulate within RGC axons proximal to the infarct (Fig. 8B ) in a similar manner to that observed during ON crush and experimental glaucoma.
Relationship between IL-6 and Gap43 following optic nerve injury
Following ON crush, rat RGCs attempt to repair/regenerate their damaged axons (Blaugrund et al., 1993; Doster et al., 1991; Leon et al., Fig. 4 . Localisation of IL-6 to injured RGC axons during experimental glaucoma. (A) Accumulation of IL-6 at the ONH at various times following induction of experimental glaucoma. In normal rats, minimal IL-6 is associated with RGC axons. By 8 h after induction of chronic ocular hypertension, accumulation of IL-6 is evident within some axons in the pre-and post-laminar ONH (arrows). At 24 h, intense IL-6 immunoreactivity is typically observed throughout the ONH. Analysis of rats at 3 days and 7 days shows IL-6 immunolabelling in the ONH remains high, although not as widespread as 1 day. By 14 days, few axons are immunopositive for IL-6. Ret, retina. (B) IL-6 accumulation is restricted to the ONH during experimental glaucoma. Three levels of the ON of a typical 2 day rat are shown. A transverse section taken through the unmyelinated neck region (lamina) shows widespread IL-6 immunolabelling. In contrast, sections taken more distally through the myelinated medial ON and optic chiasm are negative for IL-6. (C) Localisation of IL-6 within the retina during experimental glaucoma. In normal rats, only low intensity IL-6 is associated with RGC somas. By 7 days after induction of chronic ocular hypertension, RGC somas and their axons (arrows) within the central nerve fibre layer display enhanced immunoreactivity for IL-6 (arrows). GCL, ganglion cell layer; INL, inner nuclear layer. Scale bars: A and B, 100 μm; C, 50 μm.
2000)
. Delineation of the process, which is aborted at the site of injury, is traditionally achieved by immunolabelling for Growth-Associated Protein 43 (Gap43). We have recently shown that a similar phenomenon occurs during experimental glaucoma, with regenerative fibres failing to progress further than the ONH . We hypothesised that induction of IL-6 following axonal injury may be an early part of the endogenous axonal regenerative process. To explore this possibility, we first compared expression of IL-6 and Gap43 after induction of elevated IOP and ON crush in order to ascertain whether IL-6 is localised to regenerating axons (Figs. 9 and 10 ). Subsequently, we investigated the effect of administering IL-6 on Gap43-positive, neurite growth in tissue culture (Fig. 11) .
At 24 h after induction of raised IOP, RGCs axons at the ONH featured abundant IL-6 immunoreactivity, but minimal Gap43 immunoreactivity (Fig. 10) . By 3 days, limited Gap43 expression was detectable in IL-6 positive axons of some rats at the level of the prelaminar ONH (Figs. 9A,B; Fig. 10 ). By 7 days, Gap43 expression had increased considerably, such that it was typically more abundant than IL-6 within axons in the ONH (Figs. 9C-F; Fig. 10 ). By 14 days, there were usually substantially more Gap43-positive axons than IL-6-labelled axons; however, colocalisation of the two markers was still evident in some fibres, both in the prelaminar ONH and the lamina (Figs. 9G-K; Fig. 10) .
At 1 days after ON crush, axons proximal to the crush site were always Gap43-negative, but IL-6-and APP-positive (Gap43 grade 0.0 ± 0.0; IL-6 grade 4.0 ± 0.0; APP grade 4.0 ± 0.0). By 14 days, axons proximal to the crush site were always Gap43-positive, frequently IL-6 positive, but rarely APP-positive (Gap43 grade 3.8 ± 0.2; IL-6 grade 2.6 ± 0.3; APP grade 1.5 ± 0.3).
Effect of IL-6 on neuritogenesis of adult RGCs in culture
The overall data indicated that IL-6 was upregulated by injured axons prior to Gap43 and continued to be expressed, to a lesser extent, during the regenerative process. Evidence obtained from the study of spinal axons supports the notion that conditional injury-induced upregulation of IL-6 facilitates an environment favourable to axonal regeneration (Cafferty et al., 2004; Cao et al., 2006) . To establish whether IL-6 directly promotes growth of RGC axons, we investigated the effect of administering IL-6 on neuritogenesis in cultured adult RGCs.
Two experimental regimes were tested: the effect of IL-6 alone, in order to determine whether this factor could actually initiate neuritogenesis, and, IL-6 in combination with a previously-established cocktail of growth factors (Pang et al., 2007) , to delineate whether it could merely enhance or assist in the extension of already-instigated fibres. Results are shown in Fig. 11 . After 7 days in culture, there were very few RGCs present with neurites of more than 200 μm in length when neither IL-6 nor the growth factor cocktail had been applied. The presence of IL-6 significantly enhanced both neuritogenesis, as delineated by increased numbers of neurites emanating from the cell perikarya, and neurite extension, as determined by quantifying neurite lengths. In addition, the presence of the growth factor cocktail led to a marked increase in both neurite numbers and their mean length, and this was further significantly enhanced by IL-6.
Discussion
It is increasingly recognised that chronically activated glia contribute to the pathology of various neurodegenerative diseases, including glaucoma. One means by which this can occur is through the release of neurotoxic, proinflammatory factors (Lull and Block, 2010 ). In the current study, we investigated the spatio-temporal patterns of expression of three such cytokines, IL-1β, TNFα and IL-6, in a validated rat model of experimental glaucoma. We had envisaged that resident glia, particularly those located within the ONH -the pivotal site of injury during experimental glaucoma (Buckingham et al., 2008; Chidlow et al., 2011b; Howell et al., 2007; Jakobs et al., 2005; Martin et al., 2006; Salinas-Navarro et al., 2010 ) -would respond to progressive axonal injury with a co-ordinated upregulation of these cytokines. The overall results of the study were, therefore, surprising: we found only weak evidence for synthesis of IL-1β and TNFα following induction of ocular hypertension; however, we uncovered evidence that IL-6 is expressed by injured RGCs and transported within axons to the site of damage within the ONH. As shown by data Fig. 6 . Double labelling immunofluorescence of IL-6 with glial markers in representative rats killed at 2 days after induction of experimental glaucoma. IL-6 fails to colocalise with the microglial marker iba1 (A-C). There is also no colocalisation with the Müller cell marker glutamine synthetase in the retina or prelaminar ONH (D-F). Three representative images are shown of IL-6 double labelling with the astrocytic marker GFAP: (G) displays the prelaminar ONH; (H) highlights the neck/transition region of the ONH; (I) shows the neck region of the ONH in transverse orientation. In none of these images is there any obvious colocalisation of IL-6 with GFAP. Glut Syn, glutamine synthetase; ret, retina. L, longitudinal; TS, transverse. Scale bar: 100 μm.
Table 1
Level of IL-6 protein in the retina at 6 h after LPS treatment and 1 day after experimental glaucoma. 
Table 2
Grading of IL-6 and APP immunoreactivities at various times after induction of experimental glaucoma and optic nerve crush.
Glaucoma
Cont eyes 1 day (n =7) 3 days (n =8) 7 days (n = 13) 14 days (n = 21)
Integral ΔIOP ⁎ -16.6 ± 1.9 46.4 ± 11.4 91.5 ± 8.8 186.7 ± 12.4 Maximal ΔIOP ⁎ -24.3 ± 3.9 26.6 ± 4.9 25.5 ± 1.9 25.8 ± 1.1 Terminal ΔIOP ⁎ -22.0 ± 3.4 14.4 ± 6.4 9.3 ± 1.9 6.0 ± 1.1 APP grade 0.0 ± 0.0 3.7 ± 0. obtained from alternative models, injury to the ON, rather than elevated IOP, appeared to be the stimulus for IL-6 upregulation. Furthermore, the response was not characteristic of cytokines in the gp130 family. We further showed that IL-6 colocalised with Gap43 in some putative regenerating axons and that this cytokine induced neuritogenesis in RGC cultures, supporting the view that IL-6 is involved in the post-trauma attempts of injured RGCs to regenerate their axons. IL-6 is normally present at low levels in the CNS, but is upregulated in numerous acute and chronic neurodegenerative conditions. Astrocytes, microglia and neurons have all been shown to be sources of the cytokine in differing circumstances (Spooren et al., 2011) . In the retina, IL-6 is expressed by microglia during ischemia-reperfusion injury (Sanchez et al., 2003) and, as shown in the present study, NMDA-induced excitotoxicity and endotoxin challenge. In addition, cultured microglia increase IL-6 release when subjected to raised hydrostatic pressure (Sappington et al., 2006) . It is evident, therefore, that microglia are the dominant retinal cell type responsible for IL-6 synthesis following acute neuroinflammatory injuries. The most striking finding in the present study was the observation that not only was IL-6 detected in RGCs, but that it also underwent orthograde axonal transport following injury to the ON, such as occurs during experimental glaucoma and ON crush, accumulating at sites of axonal disruption. The patterns of IL-6 immunoreactivity during the first 7 days after ON injury were essentially identical to those of APP, the well-studied and conventional endogenous marker of axonal transport disruption in the ON (Chidlow et al., 2011b; Morin et al., 1993) . In fact, IL-6 afforded superior signal-to-background immunolabelling compared with APP. This is possibly due to the fact that the cytokine is only induced in RGCs with injured axons, whereas APP undergoes routine orthograde and retrograde transport in all RGC axons, as illustrated by its accumulation on the distal as well as proximal side of the crush site. We would therefore strongly advocate the use of IL-6 as a marker of ON axonal transport failure in future studies. Axonal transport and release of IL-6 has been described in cultured cortical neurons treated with IL-1β plus a depolarizing agent (Tsakiri et al., 2008) , but, to our knowledge, this is the first in vivo study to demonstrate that IL-6 is upregulated by injured neurons and conveyed to the site of axonal injury. Of note, the response of IL-6 adds further weight to the hypothesis that the ONH is the pivotal site of RGC injury following moderate elevation of IOP.
Two previous studies in rats have investigated the expression of IL-6 during experimental glaucoma: Sappington and Calkins (2008) used a chronic mouse model and observed enhanced IL-6 immunolabelling in the ganglion cell layer, a proportion of which was associated with microglia, whilst Johnson et al. (2012) made use of the hypertonic saline rat model and reported a significant, early upregulation of IL-6 mRNA in the ONH. We uncovered no evidence of IL-6 localisation within retinal microglia following induction of elevated IOP, although we did measure a highly significant upregulation in overall retinal IL-6 gene expression. It is logical to infer that the increased mRNA level was largely due to synthesis by RGCs, but expression by other cell types, including microglia, is also possible. Regarding the ONH, the cell types responsible for the elevated IL-6 mRNA measured by Johnson et al. (2011) are unknown. Since the hypertonic saline model has similar characteristics and displays a similar pathology to the laser model used herein, we might anticipate the models would also feature similar pathogeneses. We were unable to detect any IL-6 immunoreactivity within glial cells of the ONH and tentatively suggest that the mRNA might be contained Fig. 7 . Representative images of CNTF expression in the retina and optic nerve of control rats and in rats subjected to experimental glaucoma. In the normal retina (A), CNTF immunoreactivity is predominantely associated with astrocytes (small arrow), although some Müller cell somas (large arrow) and radial processes (arrowhead) are delicately labelled. At 7 days after induction of chronic ocular hypertension (B), upregulated CNTF expression is discernible in both retinal cell types. CNTF colocalises with the Müller cell marker glutamine synthetase (C). In the ONH (D) and proximal ON (G) of normal rats, CNTF is expressed by glial cells. During experimental glaucoma, only minor upregulation of CNTF in the ONH (E) and proximal ON (H) is noted. CNTF colocalises almost totally with the small heat shock protein αB-crystallin (F). In contrast, there is no presence of CNTF within injured axons, as indicated by the lack of colocalisation with APP. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; ret, retina; CNTF ciliary neurotrophic factor; Glut Syn, glutamine synthetase; APP, β-amyloid precursor protein; αB-crys, αB-crystallin. Scale bars: A-C and G-I, 25 μm; D-F, 50 μm.
within injured axons; however, we certainly cannot discount the possibility that glial cells synthesise IL-6 mRNA nor that glial cells release IL-6 which is then taken up by axons.
The stimulus for IL-6 synthesis and axonal transport during experimental glaucoma must arise from axonal injury rather than ocular hypertension, as the response was identical after ON crush and bilateral occlusion of the carotid arteries, each of which causes damage to the proximal ON without elevating IOP. This conclusion is supported by the results of previous studies, which have documented induction of IL-6 mRNA synthesis in peripheral (Ito et al., 1998; Murphy et al., 1995 Murphy et al., , 1999 and central (Hans et al., 1999) neurons in response to axonal injury. The induction of IL-6 mRNA synthesis in peripheral neurons was shown to be prevented by administration of colchicine, which blocks retrograde axonal transport, to the nerve stump, leading the authors to conclude that a factor arising from the nerve stump was responsible (Murphy et al., 1999) .
IL-6 is a member of the family of cytokines that all utilise the signal-transducing receptor subunit, gp130 (Spooren et al., 2011) . To impart perspective on the IL-6 results, we investigated expression of another family member, CNTF, after ON injury. CNTF is a survival factor for RGCs after injury and has been shown to be an important factor involved in RGC axonal regeneration after ON crush (Wen et al., 2012) . In contrast to IL-6, CNTF was localised exclusively to glial cells in the retina and ONH following induction of ocular hypertension and ON crush, findings consistent with previous accounts of CNTF distribution after excitotoxic and ischemia-reperfusion injuries (Honjo et al., 2000; Ju et al., 1999) . Future work needs to ascertain the patterns of expression of other gp130 family members subsequent to ON injury, in particular Leukemia inhibitory factor, a cytokine that has many similar attributes to IL-6.
The function of IL-6 produced as a consequence of ON injury is presently unknown. Whilst traditionally viewed as a proinflammatory cytokine, interleukin-6 is now known to have numerous roles in the CNS including as an activator of the immune system (Scheller et al., 2011) , in mediating neuronal differentiation and homeostasis as well as astrocyte generation (Spooren et al., 2011) . Importantly, IL-6 is also increasingly recognised as exerting neuroprotective, neurotrophic and neuroregenerative properties. In the peripheral nervous system, numerous studies have shown that IL-6 plays a key role in axonal regeneration after nerve lesion (see Spooren et al., 2011 for review) , whilst in the CNS, IL-6 promotes sprouting and functional recovery in lesioned hippocampal slice cultures (Hakkoum et al., 2007) . Given our results showing, firstly, that IL-6 colocalises with Gap43 in some putative regenerating axons, and secondly, that it stimulates neuritogenesis in adult RGC cultures, it is tempting to speculate that this cytokine plays an important role in the process whereby RGCs attempt to regenerate their injured axons. This process of innate attempted regeneration of RGC axons, which has been demonstrated to occur after ON crush (Benowitz and Yin, 2008) and experimental glaucoma (Chidlow et al., 2011b) , fails at the site of nerve injury, presumably as a consequence of inhibitory factors, the maturation state of the neurons in question and the formation and presence of a glial scar (Berry et al., 2008) . Of interest are the results of a recent study, which showed that endogenous regeneration of RGC axons after ON crush was enhanced by prior induction of experimental glaucoma (Lorber et al., 2012) . The authors, who used the same experimental glaucoma model as in the present study, provided data consistent with the view that activated retinal glia mediate part of this response. Given the enhanced IL-6 synthesis that occurs in the present model, however, we would suggest that this too plays a role. In support of this view, Streit et al. (2000) analysed regeneration in three different peripheral axotomy models, and, the only paradigm that led to regeneration showed the highest levels of IL-6 expression and the largest gliosis. The neuroregenerative role of the gp130 pathway in general, and CNTF in particular, in the ON has prompted much interest in recent years. Given our finding that IL-6 promotes neuritogenesis of RGCs and even enhances this process in the presence of CNTF, future work needs to focus more specifically on the role of IL-6 itself.
In the present study, we detected intense expression of IL-1β and TNFα by retinal microglia in response to endotoxin challenge or glutamate excitotoxicity. In contrast, no such effects were observed following elevation of IOP. This was true of the ONH as well as the retina, and was the case, irrespective of whether animals were analysed at early time points that corresponded with axonal transport disruption, or later time points that featured overt axonal and somal degeneration together with reactive gliosis. Our negative results are in agreement with those of Morrison and colleagues, who used microarray analysis to explore gene expression changes in the ONH of rats subjected to ocular hypertension and reported no evidence of upregulated IL-1β and TNFα in rats with early (Johnson et al., 2011) or late (Johnson et al., 2007) injury profiles. The present data are also compatible with the results of Perrin et al. (2005) , who compared gene expression in the peripheral and central nervous systems during Wallerian degeneration and identified marked increases in expression of IL-1β and TNFα in peripheral nerves, but minimal upregulations in central nerves. However, our results do not correspond with the finding of TNFα expression by ONH glia in human eyes with severe glaucoma (Yuan and Neufeld, 2000) . The reason for the difference may simply be that factors other than ocular hypertension cause glial expression of TNFα during advanced glaucomatous disease.
Despite not observing IL-1β or TNFα immunolabelling in rats subjected to elevated IOP, we did identify modest but significant increases in expression of both mRNAs in the retina. An increase in retinal TNFα mRNA of the same order of magnitude has previously been reported in Fig. 9 . Relationship between IL-6 and Gap43 expression in rats subjected to experimental glaucoma (A-K) and ON crush (L-N). At 3 days after induction of chronic ocular hypertension, pronounced IL-6 immunolabelling is evident within axons at the ONH (A), but little Gap43 immunoreactivity is detectable (B). By 7 days, Gap43 immunoreactivity at the ONH is strikingly higher, equalling that of IL-6 or often exceeding it (C-F). At 14 days, intense Gap43 immunoreactivity is typically observed at the ONH, whilst the abundance of IL-6 has declined markedly (G, H); nevertheless, the two markers colocalise in some putative regenerating fibres, as seen in the lamina of this rat (I-K). At 14 days following ON crush, axons proximal to the crush site are always Gap43-positive and frequently IL-6 positive, as shown in this representative rat (L-N). neck, neck region of ONH; transition, transition region of ONH. Scale bar: A-H and L-N, 50 μm; I-K, 25 μm. an induced mouse model of glaucoma (Nakazawa et al., 2006) , although as with our study the cell types responsible were not identified. There are three plausible explanations for the disconnect between the mRNA and protein results: (1) the mRNAs were not translated; (2) the proteins were only transiently expressed by individual cells or rapidly degraded, either scenario of which would make immunohistochemical detection more challenging; (3) the tissue level of the proteins was below the detectable limit of the relevant assays. In support of the first possibility, discrepancies between IL-1β and TNFα mRNA and protein levels have been widely reported in the literature, as for example in rodent models of Wallerian degeneration (Shamash et al., 2002) , forebrain ischemia (Sairanen et al., 1997) , myocardial infarction (Kaur et al., 2006) and arthitis (Rioja et al., 2004) . One theory that has been proposed to account for the phenomenon relates to "priming", in which a detrimental stimulus induces transcription but not translation of a cytokine in a population of cells, leaving them in a "primed" state. A subsequent detrimental stimulation then results in a rapid, exaggerated release of the cytokine (Schindler et al., 1990) . The second scenario is arguably less convincing. Expression of IL-1β and TNFα after treatment with LPS or NMDA is transient in nature, yet, immunopositive microglia were detectable in every tissue section analysed from every animal. It is implausible that we could have failed to identify any positive labelling in any animal with experimental glaucoma. In our opinion, the final explanation has the most credibility. The cytokines are known to be present in very low quantities under physiological conditions. Although the mRNAs were upregulated maximally 4-fold during ocular hypertension, these increases are modest compared with typical responses to other injuries. For example, Nakazawa et al. (2007) , measured a 25-fold upregulation of IL-1β mRNA in the rat retina after NMDA treatment, despite using a substantially lower dose of NMDA than in the present study. Given the far greater sensitivity of real-time PCR compared to immunohistochemistry, it is entirely feasible that the levels of both cytokines, although augmented relative to control animals, remained too low to visualise. Overall, our results do not provide support for the theory that glial cells secrete IL-1β and TNFα in response to ocular hypertension; however, they do not contradict previous work in mice that advocates an important role for TNFα in the pathophysiology of experimental glaucoma (Nakazawa et al., 2006) .
